Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies.

Re, Daniel; Barrière, Jérôme; Chamorey, Emmanuel; Delforge, Margaux; Gastaud, Lauris; Petit, Emmanuel; Chaminade, Axel; Verrière, Benjamin; Peyrade, Frédéric

Re, Daniel; Barrière, Jérôme; Chamorey, Emmanuel; Delforge, Margaux; Gastaud, Lauris; Petit, Emmanuel; Chaminade, Axel; Verrière, Benjamin; Peyrade, Frédéric.

Re D; Department of Medical Oncology, Centre Hospitalier Antibes Juan-les-Pins, Antibes, France.
Barrière J; Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.
Chamorey E; Department of Medical Oncology, Clinique Saint-Jean, Cagnes-sur-Mer, France.
Delforge M; Department of Biostatistics and Epidemiology, Centre Antoine Lacassagne, Nice, France.
Gastaud L; Department of Pharmacy, Centre Hospitalier Antibes Juan-les-Pins, Antibes, France.
Petit E; Department of Medical Oncology, Centre Antoine Lacassagne, Nice, France.
Chaminade A; Department of Medical Oncology, Clinique Saint-Jean, Cagnes-sur-Mer, France.
Verrière B; Department of Medical Oncology, Clinique Saint-Jean, Cagnes-sur-Mer, France.
Peyrade F; Department of Pharmacy, Centre Hospitalier Antibes Juan-les-Pins, Antibes, France.

Leuk Lymphoma ; 62(13): 3308-3310, 2021 12.

Article in English | MEDLINE | ID: covidwho-1324511

Subject(s)

COVID-19; Hematologic Neoplasms; Antibodies, Viral; Hematologic Neoplasms/therapy; Humans; RNA, Messenger; SARS-CoV-2; Seroconversion; Vaccination

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Hematologic Neoplasms / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Leuk Lymphoma Journal subject: Hematology / Neoplasms Year: 2021 Document Type: Article Affiliation country: 10428194.2021.1957877

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google